<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768742</url>
  </required_header>
  <id_info>
    <org_study_id>CL00635</org_study_id>
    <secondary_id>HC-126128</secondary_id>
    <nct_id>NCT00768742</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study</brief_title>
  <acronym>FAST</acronym>
  <official_title>Clinical Study to Assess the Safety and Effectiveness of VizAblate(tm) Intrauterine Ultrasound-guided RF Ablation (IUUSgRFA) of Submucosal and Intramural Uterine Fibroids on the Reduction of Pictorial Blood Loss Assessment Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynesonics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynesonics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that a minimum 75% volume
      radiofrequency ablation of fibroids associated with menorrhagia results in reduction of
      menstrual bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study revised and reinitiated under another protocol
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual bleeding as measured by the Pictorial Blood Loss Assessment Chart (PBLAC)</measure>
    <time_frame>Baseline, 3 mo, 6 mo, 9 mo, 12 mo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical reintervention</measure>
    <time_frame>12 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaires</measure>
    <time_frame>Baseline, 3 mo, 6 mo, 9 mo, 12 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to return to normal daily activity</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At time of discharge, 7-14 days, 3 mo, 6 mo, 9 mo, 12 mo.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject tolerance of procedure rated via analog visual scale</measure>
    <time_frame>Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroid dimension and non-perfused volume</measure>
    <time_frame>Baseline, 1 day, 3 mo, 6 mo, 9 mo, and 12 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy and pregnancy-related complications</measure>
    <time_frame>3 mo, 6 mo, 9 mo, and 12 mo</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Leiomyoma</condition>
  <condition>Uterine Fibroids</condition>
  <condition>Menorrhagia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VizAblate Intrauterine Ultrasound-Guided RF Ablation</intervention_name>
    <description>VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal

          -  Regular, consistent menstrual cycles

          -  Serum progesterone &gt; 6 ng/ml (19 nmol/L)

          -  2 months history of PBLAC score of 150-500

          -  Maximum of 4 type I, type II, or intramural fibroids

          -  Patient is at low risk for cervical cancer

          -  Hemoglobin &gt; 6 g/dl

          -  Not at risk for pregnancy

          -  No desire for future fertility

          -  Willing and able to complete the follow-up requirements outlined in the study design
             section of the protocol

          -  Willing to sign a consent form

        Exclusion Criteria:

          -  Subserosal fibroids.

          -  Any fibroid that obstructs access to the endometrial cavity

          -  FSH &gt; 20 IU/L

          -  Pregnancy

          -  Evidence of disorders of hemostasis

          -  Use of GnRH agonist or depomedroxyprogesterone acetate or other implantable or
             injectable progestin and/or estrogen

          -  SERMS/SPRMS within the last 6 months

          -  Current use of any IUD or use of Mirena IUS within the last 3 months

          -  Gynecological malignancy or hyperplasia

          -  Known/suspected abdominal/pelvic cancer

          -  Active pelvic infection (e.g., active salpingitis or other pelvic inflammatory
             disease)

          -  Adenomyosis

          -  Previous surgical or ablative treatment for fibroids or menorrhagia

          -  Previous uterine artery embolization or occlusion

          -  Patient on anti-coagulation therapy

          -  Needing emergency surgery to treat fibroid symptoms

          -  Concomitant intrauterine polyps.

          -  Major medical or psychiatric illness affecting general health or patient's ability to
             comply with follow-up schedule or provide valid patient self-assessment data

          -  Contraindication to MRI

          -  Allergy to contrast media

          -  Mild renal insufficiency or worse

          -  Known renal disease

          -  Uncontrolled hypertension lasting 2 years or more

          -  Diabetes

          -  Uterine size &gt; 10 weeks or 10 cm from ectocervix to fundus.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Toub, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Gynesonics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Victoria General Hospital; Mature Women's Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirley E. Greenberg Women's Health Centre, The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroid RF Ablation</keyword>
  <keyword>Intrauterine Ultrasound</keyword>
  <keyword>VizAblate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

